No disclosed relationships extracted for ABCLyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
How ABCL has moved on past release days vs its typical ±3.2% day, and how often it closed up. Computed from daily closes — not a forecast.